ReviewExpert review of cardiovascular therapy2015
Developments in the management of Chagas cardiomyopathy.
Review in Expert review of cardiovascular therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 3 syntheses or guidelines pooled it, 82 citations in OpenAlex.
- The economic burden of Chagas disease: A systematic review.PLoS neglected tropical diseases · 2023Pooled it
- Galectin-3 and fibrosis intensity in Chronic Chagas Cardiomyopathy: a systematic review.Revista do Instituto de Medicina Tropical de Sao Paulo · 2022Pooled it
- Increased mortality attributed to Chagas disease: a systematic review and meta-analysis.Parasites & vectors · 2016Pooled it
- IL-33/ST2 Signaling Protects the Heart by Restraining Inflammation and Parasite Burden duringACS infectious diseases · 2026Article
- Evaluation of the trypanocidal and immunomodulatory effects of LDT409, a cardanol derivative from cashew nut shell liquid.Frontiers in immunology · 2026Article
- Effect of neurohormonal therapeutic in left ventricle global and regional function in Chagas cardiomyopathy in a translational animal experimental model.Scientific reports · 2025Article
- Structure-Based Identification of Non-covalent Prolyl Oligopeptidase 80 Inhibitors TargetingJournal of chemical information and modeling · 2025Article
- Cardiovascular outcomes of chagas-induced non-ischemic cardiomyopathy versus other nonischemic cardiomyopathies: a regression matched national cohort analysis.American journal of cardiovascular disease · 2025Article
- Animal models for exploring Chagas disease pathogenesis and supporting drug discovery.Clinical microbiology reviews · 2024Review
- Cardiac involvement in Chagas disease and African trypanosomiasis.Nature reviews. Cardiology · 2024Review
- Unraveling the Missing Pieces: Exploring the Gaps in Understanding Chagas Cardiomyopathy.Cureus · 2024Review
- Infectious factors in myocarditis: a comprehensive review of common and rare pathogens.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2024Review
- Exploring Peripheral Blood-Derived Extracellular Vesicles as Biomarkers: Implications for Chronic Chagas Disease with Viral Infection or Transplantation.Microorganisms · 2024Article
- Signatures of CD4Frontiers in immunology · 2024Article
- The Therapeutic Potential of Angeli's Salt in Mitigating AcutePathogens (Basel, Switzerland) · 2023Article
- Metallic Nanoparticles and Core-Shell Nanosystems in the Treatment, Diagnosis, and Prevention of Parasitic Diseases.Pathogens (Basel, Switzerland) · 2023Review
- Metabolomic Profiling of End-Stage Heart Failure Secondary to Chronic Chagas Cardiomyopathy.International journal of molecular sciences · 2022Article
- Experimental Combination Therapy with Amiodarone and Low-Dose Benznidazole in a Mouse Model of Trypanosoma cruzi Acute Infection.Microbiology spectrum · 2022Article
- Review
- Leishmaniasis and Chagas disease: Is there hope in nanotechnology to fight neglected tropical diseases?Frontiers in cellular and infection microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
Abstract
Over 100 years have elapsed since the discovery of Chagas disease and there is still much to learn regarding pathogenesis and treatment. Although there are antiparasitic drugs available, such as benznidazole and nifurtimox, they are not totally reliable and often toxic. A recently released negative clinical trial with benznidazole in patients with chronic Chagas cardiomyopathy further reinforces the concerns regarding its effectiveness. New drugs and new delivery systems, including those based on nanotechnology, are being sought. Although vaccine development is still in its infancy, the reality of a therapeutic vaccine remains a challenge. New ECG methods may help to recognize patients prone to developing malignant ventricular arrhythmias. The management of heart failure, stroke and arrhythmias also remains a challenge. Although animal experiments have suggested that stem cell based therapy may be therapeutic in the management of heart failure in Chagas cardiomyopathy, clinical trials have not been promising.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.